Author: Doggrell, Sheila A

Source: Expert Opinion on Therapeutic Targets, Volume 10, Number 4, August 2006 , pp. 627-630(4)

Publisher: Informa Healthcare

Abstract:

Rheumatoid arthritis and systemic lupus erythematosus are autoimmune diseases, which may involve phosphoinositide 3-kinase gamma (PI3Kγ). AS605240 is a new and selective PI3Kγ inhibitor. The direct administration of collagen II-specific antibodies produced the features of rheumatoid arthritis in mice, and when AS605240 was administered orally after the collagen antibodies, it reduced the clinical and histological signs of joint inflammation. Collagen can also be used to induce the clinical and histopathological symptoms similar to rheumatoid arthritis in mice and this can be prevented or reduced by treatment with AS605240. MRL-lpr mice develop lupus-like disease and AS605240 prolonged the life of these mice. MRL-lpr mice also develop kidney disease and this can be reversed with AS605240 treatment. These results suggest that PI3Kγ is a therapeutic target in chronic inflammation and that the PI3Kγ inhibitor AS605240 may have potential in the treatment of chronic inflammatory conditions.

Keywords: AS605240; chronic inflammation; phosphoinositide 3-kinase-γ; rheumatoid arthritis; systemic lupus erythematosus

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14728222.10.4.627

Publication date: 2006-08-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Doggrell, Sheila A

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers